PREDICTIVE MARKERS FOR AORTIC ATHEROMATOSIS AND MITRAL ANNULAR CALCIFICATION IN TYPE 2 DIABETES PATIENTS WITHOUT ESTABLISHED CARDIOVASCULAR DISEASE

被引：0
|
作者：
Grigorescu, Elena-Daniela [1 ]
Lacatusu, Cristina-Mihaela [1 ]
Floria, Mariana [2 ]
Cazac, Georgiana-Diana [1 ]
Onofriescu, Alina [1 ]
Ceasovschih, Alexandr [2 ]
Golforoush, Pelin Arabacilar [3 ]
Sorodoc, Victorita [2 ]
Sorodoc, Laurentiu [2 ]
Mihai, Bogdan-Mircea [1 ]
机构：
[1] Grigore T Popa Univ Med & Pharm Iasi, Diabet, Iasi, Romania
[2] Grigore T Popa Univ Med & Pharm Iasi, Internal Med, Iasi, Romania
[3] UCL, Hatter Cardiovasc Inst, London, England
来源：
ATHEROSCLEROSIS | 2024年 / 395卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P312
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Achievement of cardiovascular goals in patients diagnosed with type 2 diabetes with and without cardiovascular disease
    Garzon, Gerardo
    Gil, Angel
    Maria Herrero, Ana
    Jimenez, Fernando
    Jose Cerezo, Maria
    Dominguez, Cristina
    GACETA SANITARIA, 2015, 29 (06) : 425 - 430
  • [42] The potential DNA methylation markers of cardiovascular disease in patients with type 2 diabetes
    He, Yunbiao
    Chen, Xia
    Liu, Mingliang
    Zuo, Lei
    Zhai, Zhiyu
    Zhou, Long
    Li, Guangzhen
    Chen, Li
    Qi, Guolong
    Jing, Chunxia
    Hao, Guang
    BMC MEDICAL GENOMICS, 2023, 16 (01)
  • [43] The potential DNA methylation markers of cardiovascular disease in patients with type 2 diabetes
    Yunbiao He
    Xia Chen
    Mingliang Liu
    Lei Zuo
    Zhiyu Zhai
    Long Zhou
    Guangzhen Li
    Li Chen
    Guolong Qi
    Chunxia Jing
    Guang Hao
    BMC Medical Genomics, 16
  • [44] Pioglitazone treatment and cardiovascular event and death in subjects with type 2 diabetes without established cardiovascular disease (JDDM 36)
    Yokoyama, H.
    Araki, S.
    Kawai, K.
    Hirao, K.
    Oishi, M.
    Sugimoto, K.
    Sone, H.
    Maegawa, H.
    Kashiwagi, A.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2015, 109 (03) : 485 - 492
  • [45] The Implication of NT-proBNP in the Assessment of the Clinical Phenotype of Patients with Type 2 Diabetes Mellitus, Without Established Cardiovascular Disease
    Gastouniotis, Ioannis
    Fragoulis, Christos
    Antonopoulos, Alexis
    Kouroutzoglou, Alexandrina
    Noutsou, Marina
    Thanopoulou, Anastasia
    Chrysohoou, Christina
    Tsioufis, Konstantinos P.
    BIOMEDICINES, 2024, 12 (12)
  • [46] GLP-1RAs for Ischemic Stroke Prevention in Patients With Type 2 Diabetes Without Established Atherosclerotic Cardiovascular Disease
    Yang, Yi-Sun
    Chen, Hsin-Hung
    Huang, Chien-Ning
    Hsu, Chung Y.
    Hu, Kai-Chieh
    Kao, Chia-Hung
    DIABETES CARE, 2022, 45 (05) : 1184 - 1192
  • [47] Signs of myocardial fibrosis in patients with type 2 diabetes without cardiovascular disease
    Zubovych, I. V.
    Marushko, Y. Y.
    Saienko, Y. A.
    Halchenko, O. G.
    Vebs, D. C.
    Mankovsky, B. M.
    DIABETOLOGIA, 2024, 67 : S461 - S462
  • [48] Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
    Ramos, Mafalda
    Men, Peng
    Wang, Xu
    Ustyugova, Anastasia
    Lamotte, Mark
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2021, 19 (01)
  • [49] Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
    Mafalda Ramos
    Peng Men
    Xu Wang
    Anastasia Ustyugova
    Mark Lamotte
    Cost Effectiveness and Resource Allocation, 19
  • [50] Effect of empagliflozin beyond glycemic control: Cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease
    Monteiro, Pedro
    Aguiar, Carlos
    Matos, Pedro
    Silva-Nunes, Jose
    Birne, Rita
    Branco, Patricia
    Calado, Joaquim
    Melo, Miguel
    Polonia, Jorge
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2019, 38 (10) : 721 - 735
12345